Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 6/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 3/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | PYGL | P06737 | 2/20 | 0.31 |
| ▸ | PYGM | P11217 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21882296 | 0.85 | CSF1R (0.34) | TGFBR1KDRCSF1RPDGFRAPDGFRB | |
| SCHEMBL21882304 | 0.79 | CSF1R (0.33) | TGFBR1KDRCSF1RPDGFRAPDGFRB | |
| SCHEMBL21882305 | 0.77 | RAF1 (0.38) | CSF1RPDGFRAPDGFRBBRAF | |
| SCHEMBL21882567 | 0.76 | CSF1R (0.42) | TGFBR1KDRCSF1RPDGFRAPDGFRB | |
| SCHEMBL25248350 | 0.76 | TGFBR1 (0.39) | TGFBR1CSF1RPDGFRAPDGFRBKIT | |
| SCHEMBL30890883 | 0.76 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL30086838 | 0.76 | TGFBR1 (0.39) | TGFBR1CSF1RPDGFRAPDGFRBKIT | |
| SCHEMBL16029255 | 0.76 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL21426336 | 0.74 | TGFBR1 (0.47) | TGFBR1KDRCSF1RPDGFRAPDGFRB | |
| SCHEMBL21425579 | 0.73 | TGFBR1 (0.45) | TGFBR1CSF1RPDGFRAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632907-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |